Companies in #Diffuse Large B-Cell Lymphoma (DLBCL)
Found 1 company operating in this sector.
ADC Therapeutics is a commercial-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for the treatment of hematologic cancers and solid tumors. Its lead product Zynlonta (loncastuximab tesirine) is the first CD19-targeted ADC approved for relapsed/refractory diffuse large B-cell lymphoma. The company is advancing a pipeline of next-generation ADCs targeting both hematologic malignancies and selected solid tumors.